Pneumococcal infections and protection with vaccination in adult chronic lung diseases


Karadeniz G., Kilinc O., Olmez A., ÖZHAN M. H. , ÖZLÜ T., Ozyurek B. A. , ...Daha Fazla

TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, cilt.68, sa.3, ss.305-320, 2020 (ESCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 68 Konu: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5578/tt.70012
  • Dergi Adı: TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX
  • Sayfa Sayıları: ss.305-320

Özet

Pneumococcal infections are an important cause of mortality and morbidity in Chronic Lung Diseases. However, exacerbations, which make the treatment of diseases very difficult, and corticosteroids used during treatment carry a great risk of pneumococcal infection and adversely affect the treatment. The most rational way to reduce the negative impact of pneumococcal infections on the clinical and economic burden of Chronic Lung Diseases is vaccination of the risky population. Although, vaccination recommendations are well defined, recommended by national and international guidelines and are paid by health authorities, in Turkey, vaccination rates in adults with chronic lung disease is far below the expected. Since physicians are considered to be the most important and reliable resource that can guide their patients in vaccination, applying pneumococcal vaccination routinely in all patients with chronic lung diagnosis and making it a part of daily practice will greatly contribute to reducing the clinical and economic burden of pneumococcal infections in these patients. In this review, the effects of pneumococcal diseases on chronic lung diseases, the risk and clinical burden of pneumococcal diseases in chronic lung diseases are discussed in the light of guidelines and current literature, and the importance of protection from pneumonia in these patients is emphasized. In addition to general information and efficacy data about pneumococcal vaccines available in our country, application methods and access routes to vaccines are also described.